392 Lung Toxicity Induced by Novel Antineoplastic Therapies in Cancer Patients.

Background Pulmonary toxicity and respiratory failure are major adverse events complicating the use of novel antineoplastic agents in the treatment of lung cancer. We aim to investigate the risk and characteristics of cytostatic-induced pulmonary toxicity caused by agents currently used to treat lung cancer.